Zuclopenthixol Tablets Suppliers & Bulk Manufacturers
Available Forms: Oral Tablets
Available Strengths: 10 mg, 25 mg, 40 mg
Reference Brands: Clopixol®(EU)
Category:
Antipsychotropic Drugs
Zuclopenthixol tablets are typical antipsychotics that block dopamine D2 receptors in the brain, reducing psychotic symptoms like delusions, hallucinations, and aggression. They are primarily used in the oral management of schizophrenia and other chronic psychotic disorders. The tablets help maintain symptom stability and improve treatment adherence in long-term care.
Zuclopenthixol tablets is available in Oral Tablets
and strengths such as 10 mg, 25 mg, 40 mg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Zuclopenthixol tablets is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Zuclopenthixol tablets can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Zuclopenthixol tablets, used for managing schizophrenia and chronic psychoses, are not FDA-approved in the United States but are authorized in the European Union under the brand Clopixol. EU regulations require GMP compliance, pharmacovigilance systems, and bioequivalence data for registration. U.S. market entry would require a 505(b)(2) or ANDA submission with complete CMC, clinical, and labeling documentation. Regulatory focus includes psychiatric safety profiling and consistent release characteristics. For dossier-ready Zuclopenthixol tablets and to explore other available forms such as IM injections and depot formulations, visit Pharmatradz.com — your trusted platform for global pharmaceutical sourcing.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing